These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31150294)

  • 1. Systematic review of the pharmacoeconomics of Parkinson disease medications.
    Wang AS; Gunzler SA
    Expert Opin Pharmacother; 2019 Sep; 20(13):1659-1670. PubMed ID: 31150294
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.
    Reese JP; Dams J; Winter Y; Balzer-Geldsetzer M; Oertel WH; Dodel R
    Expert Opin Pharmacother; 2012 May; 13(7):939-58. PubMed ID: 22475391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 4. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
    Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
    World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic evaluation of pharmacotherapies for Parkinson's disease.
    Coyle D; Barbeau M; Guttman M; Baladi JF
    Parkinsonism Relat Disord; 2003 Jun; 9(5):301-7. PubMed ID: 12781598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.
    Scheife RT; Schumock GT; Burstein A; Gottwald MD; Luer MS
    Am J Health Syst Pharm; 2000 May; 57(10):953-62. PubMed ID: 10832495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of pramipexole in Parkinson's disease in the US.
    Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
    Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Stage-Based Approach to Therapy in Parkinson's Disease.
    Carrarini C; Russo M; Dono F; Di Pietro M; Rispoli MG; Di Stefano V; Ferri L; Barbone F; Vitale M; Thomas A; Sensi SL; Onofrj M; Bonanni L
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31434341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for Parkinson's disease.
    Morgan JC; Sethi KD
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):403-17. PubMed ID: 16939381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of Parkinson disease: a review.
    Connolly BS; Lang AE
    JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
    Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
    Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.